The Use of Dasatinib (SPRYCEL) in Treating Patients With Polycythemia Vera (PV): A Phase II, Non-Randomized Study
1. Patients must be >= 18 years old
2. Performance Status (ECOG) 0-3
3. Previous therapies limited to interferon-alpha, hydroxyurea, anagrelide, and imatinib
4. Patients may have documented resistance or intolerance to interferon-alpha, imatinib,
hydroxyurea, or anagrelide, but must have been demonstrated to be phlebotomy
dependent requiring 6 or more phlebotomies per year to maintain the target HCT.
5. Patients may have newly diagnosed PV.
6. Patients may have had inadequate phlebotomy control on hydroxyurea or imatinib.
7. Adequate Organ Function
- Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)
- Hepatic enzymes (AST, ALT ) ≤ 2.5 times the institutional ULN
- Serum Na, K+, Mg2+, Phosphate and Ca2+³ Lower Limit of Normal (LLN)
- Serum Creatinine < 1.5 time the institutional ULN
- Hemoglobin, Neutrophil count, Platelets, PT, PTT all Grade 0-1
8. Ability to take oral medication: dasatinib tablets may be swallowed whole, or may be
ingested as a solution. Dasatinib tablets can be dissolved in juice, and can then be
administered through a nasogastric tube.
9. Women of childbearing potential (WOCBP) must have:
- A negative serum or urine pregnancy test within 72 hours prior to the start of
study drug administration
10. Persons of reproductive potential must agree to use an adequate method of
contraception throughout treatment and for at least 4 weeks after study drug is
11. Signed written informed consent including HIPAA according to institutional guidelines
1. Patients receiving busulfan within six weeks of Study Day 1.
2. Patients receiving treatment with interferon-alpha within 4 weeks of Study Day 1.
3. Patients receiving treatment with imatinib within 14 days of Study, Day 1.
4. Patients with Grade 3 or 4 cardiac problems as defined by the New York Heart
5. Patients with a history of non-compliance to medical regimens or who are considered
6. A malignancy [other than the one treated in this study], which required radiotherapy
or systemic treatment within the past 5 years.
7. Concurrent medical condition which may increase the risk of toxicity, including:
- Pleural or pericardial effusion of any grade
- Clinically-significant coagulation or platelet function disorder (e.g. known von
8. Cardiac Symptoms, consider the following:
- Uncontrolled angina, congestive heart failure or MI within (6 months)
- Diagnosed congenital long QT syndrome
- Any history of clinically significant ventricular arrhythmias (such as
ventricular tachycardia, ventricular fibrillation, or Torsades de pointes)
- Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- Subjects with hypokalemia or hypomagnesemia if it cannot be corrected
9. History of significant bleeding disorder unrelated to cancer, including:
- Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
- Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor
- Ongoing or recent (≤ 3 months) significant gastrointestinal bleeding
10. Concomitant Medications, consider the following prohibitions:
- Drugs that are generally expected to have a risk of causing Torsades de Pointes
including: (Patients must discontinue drug 7 days prior to starting dasatinib)
- The concomitant use of H2 blockers or proton pump inhibitors with dasatinib is
not recommended. The use of antacids should be considered in place of H2
blockers or proton pump inhibitors in patients receiving dasatinib therapy.
- Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy
- Patient agrees that IV bisphosphonates will be withheld for the first 8 weeks of
dasatinib therapy due to risk of hypocalcemia.
- Patient may not be receiving any prohibited CYP3A4 inhibitors
- Unwilling or unable to use an acceptable method to avoid pregnancy for the
entire study period and for at least 4 weeks after cessation of study drug, or
- Have a positive pregnancy test at baseline, or
- Are pregnant or breastfeeding